348 related articles for article (PubMed ID: 27357173)
1. Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies.
Fioretto P; Mansfield TA; Ptaszynska A; Yavin Y; Johnsson E; Parikh S
Drugs Aging; 2016 Jul; 33(7):511-22. PubMed ID: 27357173
[TBL] [Abstract][Full Text] [Related]
2. Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.
Jabbour S; Seufert J; Scheen A; Bailey CJ; Karup C; Langkilde AM
Diabetes Obes Metab; 2018 Mar; 20(3):620-628. PubMed ID: 28950419
[TBL] [Abstract][Full Text] [Related]
3. Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events.
Ptaszynska A; Johnsson KM; Parikh SJ; de Bruin TW; Apanovitch AM; List JF
Drug Saf; 2014 Oct; 37(10):815-29. PubMed ID: 25096959
[TBL] [Abstract][Full Text] [Related]
4. Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes.
Kohler S; Salsali A; Hantel S; Kaspers S; Woerle HJ; Kim G; Broedl UC
Clin Ther; 2016 Jun; 38(6):1299-1313. PubMed ID: 27085585
[TBL] [Abstract][Full Text] [Related]
5. Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials.
Kohler S; Zeller C; Iliev H; Kaspers S
Adv Ther; 2017 Jul; 34(7):1707-1726. PubMed ID: 28631216
[TBL] [Abstract][Full Text] [Related]
6. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
Wilding JP; Woo V; Rohwedder K; Sugg J; Parikh S;
Diabetes Obes Metab; 2014 Feb; 16(2):124-36. PubMed ID: 23911013
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of dapagliflozin in Asian patients: A pooled analysis.
Yang W; Ji L; Zhou Z; Cain VA; Johnsson KM; Sjöström CD
J Diabetes; 2017 Aug; 9(8):787-799. PubMed ID: 27625142
[TBL] [Abstract][Full Text] [Related]
8. Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease.
Leiter LA; Cefalu WT; de Bruin TW; Xu J; Parikh S; Johnsson E; Gause-Nilsson I
Diabetes Obes Metab; 2016 Aug; 18(8):766-74. PubMed ID: 27009868
[TBL] [Abstract][Full Text] [Related]
9. Hypersensitivity Events, Including Potentially Hypersensitivity-Related Skin Events, with Dapagliflozin in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis.
Mellander A; Billger M; Johnsson E; Träff AK; Yoshida S; Johnsson K
Clin Drug Investig; 2016 Nov; 36(11):925-933. PubMed ID: 27461213
[TBL] [Abstract][Full Text] [Related]
10. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
Ji L; Ma J; Li H; Mansfield TA; T'joen CL; Iqbal N; Ptaszynska A; List JF
Clin Ther; 2014 Jan; 36(1):84-100.e9. PubMed ID: 24378206
[TBL] [Abstract][Full Text] [Related]
11. Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function.
Petrykiv S; Sjöström CD; Greasley PJ; Xu J; Persson F; Heerspink HJL
Clin J Am Soc Nephrol; 2017 May; 12(5):751-759. PubMed ID: 28302903
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study.
Cahn A; Mosenzon O; Wiviott SD; Rozenberg A; Yanuv I; Goodrich EL; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS; Raz I
Diabetes Care; 2020 Feb; 43(2):468-475. PubMed ID: 31843945
[TBL] [Abstract][Full Text] [Related]
13. Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus.
Kinduryte Schorling O; Clark D; Zwiener I; Kaspers S; Lee J; Iliev H
Adv Ther; 2020 Aug; 37(8):3463-3484. PubMed ID: 32372290
[TBL] [Abstract][Full Text] [Related]
14. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
[TBL] [Abstract][Full Text] [Related]
15. Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials.
Johnsson K; Johnsson E; Mansfield TA; Yavin Y; Ptaszynska A; Parikh SJ
Postgrad Med; 2016 May; 128(4):346-55. PubMed ID: 26878357
[TBL] [Abstract][Full Text] [Related]
16. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
Matthaei S; Bowering K; Rohwedder K; Grohl A; Parikh S;
Diabetes Care; 2015 Mar; 38(3):365-72. PubMed ID: 25592197
[TBL] [Abstract][Full Text] [Related]
17. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
Vivian EM
Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
[TBL] [Abstract][Full Text] [Related]
18. Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension.
Cefalu WT; Leiter LA; de Bruin TW; Gause-Nilsson I; Sugg J; Parikh SJ
Diabetes Care; 2015 Jul; 38(7):1218-27. PubMed ID: 25852208
[TBL] [Abstract][Full Text] [Related]
19. Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time.
Parikh S; Wilding J; Jabbour S; Hardy E
Int J Clin Pract; 2015 Feb; 69(2):186-98. PubMed ID: 25438821
[TBL] [Abstract][Full Text] [Related]
20. Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes.
Matthaei S; Bowering K; Rohwedder K; Sugg J; Parikh S; Johnsson E;
Diabetes Obes Metab; 2015 Nov; 17(11):1075-84. PubMed ID: 26212528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]